(Repeats to attach to Reuters alert)
PARIS May 10 French drugmaker Sanofi Aventis
(SASY.PA) said on Tuesday it had won U.S. approval to market its
Fluzone Intradermal vaccine for adults, allowing for flu
injections with a very fine needle.
Sanofi has said that the new vaccine, developed with syringe
maker Becton Dickinson (BDX.N), may hurt less than standard
vaccines, does a better job of stimulating protection against
influenza and requires less of the active ingredient.
Most adult flu vaccines are given using a needle 1 inch to
1.5 inches (25 mm to 40 mm) long that goes into muscle tissue.
Sanofi's new needle is one-tenth that long, just 1.5 mm, and
the vaccine uses one-fifth the usual amount of the active
ingredient, called antigen.
The Fluzone Intradermal vaccine will be available to
healthcare providers in the U.S. for the 2011-2012 flu season,
Sanofi said in a statement.
(Reporting by Caroline Jacobs, Editing by Christian Plumb)